{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"18.7","upperLimit":"81.3","value":"50"}]}],"title":"Investigator assessment @ up to 78 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"18.7","upperLimit":"81.3","value":"50"}]}],"title":"Investigator assessment @ up to 92 months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"Overall Response Rate (ORR) was defined as the percentage of participants with stringent complete response (sCR), CR, PR, very good partial response (VGPR) by investigator assessment as defined by the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma. Specifically, ORR = number of subjects with a confirmed overall response divided by the total number of subjects in the corresponding analysis population.","dispersionType":"95% Confidence Interval","groups":[{"description":"All subjects enrolled received oral dabrafenib 150 mg bid in combination with oral trametinib 2 mg once daily. Subjects continued treatment until an unacceptable toxicity, disease progression, or death.","id":"OG000","title":"Multiple Myeloma (MM)"}],"paramType":"NUMBER","populationDescription":"ITT/Evaluable population - Primary analysis cohort","reportingStatus":"POSTED","timeFrame":"From study treatment start date until first documented complete response or partial response, assessed up to 78 months (cut-off date for FDA Submission = 14-Sep-20) and up to 92 months (cut-off date for end of study = 10-Dec-21)","title":"Overall Response Rate (ORR) in the Multiple Myeloma (MM) Cohort","type":"PRIMARY","unitOfMeasure":"Percentage of Participants"}